HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.

Abstract
The combinations of radiotherapy (RT) plus chemotherapy (CTRT) with cisplatin or, alternatively, RT plus cetuximab (RT+CET), are the treatments of choice for locally advanced squamous cell carcinoma of the head and neck (HNSCC). We performed a systematic review and meta-analysis of published studies reporting the efficacy of these 2 combined modality therapies for the treatment of locoregionally advanced HNSCC. We performed a systematic search of PUBMED, EMBASE, Web of Science, SCOPUS, and the Cochrane Register of Controlled Trials. Meta-analysis was performed using the fixed- or random-effects models. The primary endpoints were 2-year overall survival (OS), 2-year progression-free survival (PFS), and 2-year locoregional relapse (LRR), reported as risk ratios (RRs) and 95% confidence intervals (CIs). Fifteen trials, including a total of 1808 patients, were analysed. Three of these trials were prospective, and 12 were retrospective. Overall, for locally advanced HNSCC, concomitant CTRT significantly improved 2-year OS (RR=0.66; 95% CI, 0.46-0.94; P=0.02), 2-year PFS (RR=0.68; 95% CI, 0.53-0.87; P=0.002), and 2-year LRR (RR=0.63; 95% CI, 0.45-0.87; P=0.005) compared to RT+CET. For the treatment of locally advanced HNSCC, platinum-based CTRT is associated with a better OS and PFS compared to RT+CET, and this is probably attributed to improved locoregional disease control. Thus, platinum-based CTRT should remain the standard of care until equivalence with RT+CET can be prospectively demonstrated.
AuthorsFausto Petrelli, Andrea Coinu, Valentina Riboldi, Karen Borgonovo, Mara Ghilardi, Mary Cabiddu, Veronica Lonati, Enrico Sarti, Sandro Barni
JournalOral oncology (Oral Oncol) Vol. 50 Issue 11 Pg. 1041-8 (Nov 2014) ISSN: 1879-0593 [Electronic] England
PMID25176576 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Cetuximab
Topics
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, radiotherapy, therapy)
  • Cetuximab
  • Combined Modality Therapy
  • Head and Neck Neoplasms (drug therapy, radiotherapy, therapy)
  • Humans
  • Organoplatinum Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: